Skip to main content
Figure 5 | Arthritis Research & Therapy

Figure 5

From: Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics

Figure 5

Comparative effects of allopurinol and benzbromarone on plasma urate levels. Initial and final plasma urate (Pur) after standard doses of urate-lowering drugs allopurinol (300 mg/day) or benzbromarone (100 mg/day). *For final versus initial plasma urate, P < 0.01 for allopurinol groups and P < 0.001 for benzbromarone group. Adapted from [39]. Copyright 1998 with permission from BMJ Publishing Group.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us